St. Louis University

slu.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

152

Active

18

Phase 3

2

Total enrollment

12,509

Pipeline matrix

Showing 17 of 17 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Meloxicam 15 mg1
Medrol 4 MG Oral Tablet Includes Medrol Dosepak1
Gabapentin 300 mg1
Hydrocodone 5Mg/Acetaminophen 325Mg Tab1
Ketorolac 10 Mg Oral1
Cefazolin1
Cephalexin1
Acetaminophen3
Ketorolac2
Normal saline1
Oxycodone Acetaminophen1
Morphine1
Hydrocodone/Acetaminophen1
Oxycodone1
Zoledronic Acid1
Jatenzo Pill1
Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys1

Next readouts

  • 2026-06-30
  • 2026-12-31
  • 2027-01
  • 2028-06
  • 2030-09
  • 2033-09

Top conditions

  • Pregnancy6
  • Hypertension5
  • Interstitial Cystitis5
  • Opioid Use4
  • Endometriosis3
  • Gynecologic Cancer2
  • Endometrial Cancer2
  • Cervical Cancer2

Frequently asked questions about St. Louis University

How many clinical trials does St. Louis University have on ClinicalTrials.gov?
St. Louis University is listed as the lead sponsor on 152 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
How many of St. Louis University's trials are in Phase 3?
2 of St. Louis University's trials are in Phase 3, spread across 17 active drug programs.
What therapeutic areas does St. Louis University focus on?
St. Louis University's most-studied conditions on ClinicalTrials.gov are Pregnancy, Hypertension, Interstitial Cystitis, Opioid Use, Endometriosis.
When are St. Louis University's next clinical trial readouts?
St. Louis University has 6 upcoming primary-completion readouts tracked here; the soonest is “APOL1 Genetic Testing in African Americans”, expected around 2026-06-30.